The Mid Atlantic Node was among the first participants in the National Drug Abuse Treatment Clinical Trials Network. It's Regional Research and Training Center (RRTC) is comprised of distinguished faculty from Johns Hopkins University School of Medicine, Virginia Commonwealth University and Friends Research Institute as well as directors of affiliated community treatment programs (CTP's). This partnership between researchers and clinical service providers has been functioning effectively over the past 10 years and has allowed the Node to make substantial contributions to the CTN including leadership of two studies, and participation in 7 additional studies with 601 subjects enrolled during the last 5-year funding period. Importantly, the Node has an outstanding record of publication productivity with 24 publications reporting on CTN main study findings, ancillary studies and secondary analyses and supports the Chair of the CTN Publications Committee. In the upcoming grant period, the Node will maintain collaboration with VCU while expanding its affiliation with Friends Research Institute. This will bring additional faculty expertise and infrastructure support into the Node including expertise in medications development (e.g. Frank Vocci) and criminal justice research (Timothy Kinlock). We have formed broader affiliations at VCU with the Women's Health Institute (Susan Kornstein), the Institute for Drug Addiction Science (Robert Balster) and the Institute for Genetics Research (Kenneth Kendler). At Johns Hopkins, we have expanded faculty affiliates to bring in additional expertise in clinical trials, contingency management, cognitive testing, and marijuana research. We have established affiliations with the Hopkins Department of Emergency Medicine, with the School of Dentistry at University of Maryland and with the Johns Hopkins Institute for Clinical Translational Research (ICTR). Finally, we have added CTP's, including the Whitman Walker Clinic in Washington DC, that incorporate primary care, HIV care and co-occurring mental health disorders in their scope of service and a new clinic (Richmond Behavioral Health) with extensive experience in community participatory research. All these new affiliations will help the Node to meet short- and long-term expansion in the mission of CTN and to participate in a wide variety of studies that are likely to be developed. Finally, the Node will continue its strong dissemination activities that provide significant benefit to affiliated CTP's while promoting adoption of evidence-based practices.

Public Health Relevance

The Mid Atlantic Node is part of a national multi-site clinical trials network supported by the National Institute on Drug Abuse. Mission of the network is to conduct research at community treatment programs that will identify effective therapies for treatment of drug users. Subsequent adoption of new effective treatments by community programs will improve the quality of drug abuse treatment nationwide.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10DA013034-12
Application #
8135022
Study Section
Special Emphasis Panel (ZDA1-KXH-C (04))
Program Officer
Dobbins, Ronald
Project Start
1999-09-30
Project End
2015-08-31
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
12
Fiscal Year
2011
Total Cost
$1,147,669
Indirect Cost
Name
Johns Hopkins University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
McCollister, Kathryn E; Leff, Jared A; Yang, Xuan et al. (2018) Cost of pharmacotherapy for opioid use disorders following inpatient detoxification. Am J Manag Care 24:526-531
Levran, Orna; Correa da Rosa, Joel; Randesi, Matthew et al. (2018) A non-coding CRHR2 SNP rs255105, a cis-eQTL for a downstream lincRNA AC005154.6, is associated with heroin addiction. PLoS One 13:e0199951
Winhusen, Theresa; Feaster, Daniel J; Duan, Rui et al. (2018) Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection. AIDS Behav 22:2026-2032
Schwartz, R P; McNeely, J; Wu, L T et al. (2017) Identifying substance misuse in primary care: TAPS Tool compared to the WHO ASSIST. J Subst Abuse Treat 76:69-76
Lévesque, Annie; Campbell, Aimee N C; Pavlicova, Martina et al. (2017) Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. Addict Behav 65:74-80
Pan, Yue; Liu, Hongmei; Metsch, Lisa R et al. (2017) Factors Associated with HIV Testing Among Participants from Substance Use Disorder Treatment Programs in the US: A Machine Learning Approach. AIDS Behav 21:534-546
Blanco, Carlos; Campbell, Aimee N; Wall, Melanie M et al. (2017) Toward National Estimates of Effectiveness of Treatment for Substance Use. J Clin Psychiatry 78:e64-e70
Cunningham, Colin; Stitzer, Maxine; Campbell, Aimee N C et al. (2017) Contingency Management Abstinence Incentives: Cost and Implications for Treatment Tailoring. J Subst Abuse Treat 72:134-139
Campbell, Aimee N C; Montgomery, L; Sanchez, Katherine et al. (2017) Racial/ethnic subgroup differences in outcomes and acceptability of an Internet-delivered intervention for substance use disorders. J Ethn Subst Abuse 16:460-478
Lee, J D; Tofighi, B; McDonald, R et al. (2017) Acceptability and effectiveness of a web-based psychosocial intervention among criminal justice involved adults. Health Justice 5:3

Showing the most recent 10 out of 77 publications